Compare Toronto-Dominion Bank (TD) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs Tango Therapeutics Inc. — how do they compare? Toronto-Dominion Bank trades at $117.5 (market cap $191.91B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Toronto-Dominion Bank is far larger — about 51.2× Tango Therapeutics Inc.'s market cap, and Toronto-Dominion Bank pays a 2.66% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Toronto-Dominion Bank for 85 Days and Tango Therapeutics Inc. for 0 Days on average.
| TD | TNGX | |
|---|---|---|
Market Cap | $191.91B | $3.75B |
Volume | 1,115,140 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $124.80 | $32.90 |
52-Week Low | $78.72 | $7.50 |
Typical Hold Time | 85 Days | 0 Days |
Enterprise Value | $568.32B | $2.77B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TD (Toronto-Dominion Bank) trades at $117.63, up 0.98% today, with a bearish technical signal but strong fundamentals including a P/E of 18.01 and net income margin of 24.88%. Recent earnings have consistently beaten estimates, and the company announced a $10 billion share buyback program (Proactive Investors, 2026-09-30). Cash flow trends show volatility, with 2025 net cash flow at $1.08 billion. The stock faces headwinds from a high debt-to-asset ratio of 20.86 in 2025, though analyst consensus is bullish with 52.94% buy ratings.
The outlook for TD is mixed: solid profitability and shareholder returns via buybacks and dividends support upside, but technical weakness and elevated debt pose risks. Investors should weigh strong earnings momentum against macroeconomic sensitivity and regulatory scrutiny from ongoing anti-money laundering remediation. The stock's valuation appears reasonable relative to peers, but market sentiment remains cautious due to cash flow inconsistencies.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
